Annals of internal medicine
-
Multicenter Study Observational Study
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19.
Hypercoagulability may be a key mechanism of death in patients with coronavirus disease 2019 (COVID-19). ⋯ None.
-
Randomized Controlled Trial Multicenter Study
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not been established. ⋯ French Public Health Ministry.
-
Multicenter Study
Characteristics, Outcomes, and Trends of Patients With COVID-19-Related Critical Illness at a Learning Health System in the United States.
The coronavirus disease 2019 (COVID-19) pandemic continues to surge in the United States and globally. ⋯ Agency for Healthcare Research and Quality.
-
Multicenter Study
Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19 : A Retrospective Study.
The understanding of viral positivity and seroconversion during the course of coronavirus disease 2019 (COVID-19) is limited. ⋯ None.
-
Randomized Controlled Trial Multicenter Study
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention. ⋯ Bill & Melinda Gates Foundation.